Bookmark
Forward
QuickView for Midodrine (compound)
PubChem
| Name: | Midodrine |
|---|---|
| PubChem Compound ID: | 18340 |
| Description: | An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION. |
| Molecular formula: | C12H19ClN2O4 |
| Molecular weight: | 290.743 g/mol |
| Synonyms: |
Pro-Amatine (TN); Amatine; Acetamide, 2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)-, hydrochloride; ProAmatine; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide monohydrochloride; 3092-17-9; Alphamine; 43218-56-0; Metligene; D01307.
show more » |
DrugBank
Identification
| Name: | Midodrine |
|---|---|
| Name (isomeric): | DB00211 |
| Drug Type: | small molecule |
| Description: | An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION. |
| Synonyms: |
Midodrina [INN-Spanish]; Midodrin; Midodrinum [INN-Latin]; midodrine hydrochloride; Midodrine HCL
|
| Brand: | ProAmatine |
| Category: | Adrenergic alpha-Agonists, Sympathomimetics, Vasoconstrictor Agents |
| CAS number: | 133163-28-7 |
Pharmacology
| Indication: | For the treatment of symptomatic orthostatic hypotension (OH). |
|---|---|
| Pharmacology: |
Midodrine is a prodrug, i.e., the therapeutic effect of orally administered midodrine is due to the major metabolite desglymidodrine formed by deglycination of midodrine. Desglymidodrine diffuses poorly across the blood-brain barrier, and is therefore not associated with effects on the central nervous system. Administration of midodrine results in ...
show more » |
| Mechanism of Action: | Midodrine forms an active metabolite, desglymidodrine, that is an alpha1-agonist, and exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure. Desglymidodrine does not stimulate cardiac beta-adrenergic receptors. |
| Absorption: | Rapidly absorbed following oral administration. The absolute bioavailability of midodrine (measured as desglymidodrine) is 93% and is not affected by food. |
| Biotransformation: | Thorough metabolic studies have not been conducted, but it appears that deglycination of midodrine to desglymidodrine takes place in many tissues, and both compounds are metabolized in part by the liver. |
| Half Life: | The plasma levels of the prodrug peak after about half an hour, and decline with a half-life of approximately 25 minutes, while the metabolite reaches peak blood concentrations about 1 to 2 hours after a dose of midodrine and has a half-life of about 3 to 4 hours. |
| Clearance: | Renal cl=385 mL/minute |
| Toxicity: | Symptoms of overdose could include hypertension, piloerection (goosebumps), a sensation of coldness and urinary retention. The single doses that would be associated with symptoms of overdosage or would be potentially life- threatening are unknown. The oral LD50 is approximately 30 to 50 mg/kg in rats, 675 mg/kg in mice, and 125 to 160 mg/kg in dogs. Desglymidodrine is dialyzable. |
| Affected organisms: | Humans and other mammals |
Interactions
| Food interaction: |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug interaction: |
|
Targets
Enzymes
